ClinicalTrials.gg
CompletedNCT02877264Updated Nov 26, 2018

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

A Phase 1 interventional study of vapendavir 132 mg capsule and vapendavir 264 mg tablet in Healthy, sponsored by Aviragen Therapeutics. Completed at 1 site in United States. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-26.

Sponsored by Aviragen Therapeutics (part of Vaxart) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

This is a randomized, single-center, open-label, three-period, six-sequence, crossover, comparative study to evaluate the oral bioavailability of single doses of three vapendavir drug product formulations (the 264 mg free base tablet [test drug], 264 mg free base oral suspension [test drug], and two 132 mg phosphate salt capsules [reference drug]) in healthy volunteers. The study design consists of six dosing sequences. Each sequence comprises 3 periods and each subject is administered one of the three dosing formulations in the first period. A subject receives a different formulation in each of the subsequent periods, so that all subjects receive each formulation. The periods are separated by an approximate 7-day washout.

Read the detailed description

Owner of Study Record: Vaxart Inc.

02

Conditions studied

  • Healthy

Keywords

  • Vapendavir
  • Bioavailability
  • Biological Availability
  • Volunteers
03

In context

Lead sponsor

This is the only study on the registry with Aviragen Therapeutics as lead sponsor.

First submitted before Aviragen Therapeutics became part of Vaxart.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be a healthy male or female between 19 and 60 years of age (inclusive) at the time of signing the and weigh ≥50 kg with a between 18 and 32.0 kg/m2 (inclusive);
  2. Capable of giving written informed consent;
  3. Subject is able to understand and comply with the protocol requirements, instructions and restrictions;
  4. Healthy on the basis of physical examination, medical history, VS, ECGs, and clinical laboratory tests;
  5. Female subjects who are not for at least 2 years or surgically sterile with complete hysterectomy or bilateral oophorectomy and male subjects, who are not surgically sterile via vasectomy, must agree to use a double barrier method of , such as, a condom plus spermicidal agent (foam/gel/film/cream/suppository) from Study Day 0 until 30 days after completion of the study. This includes female subjects who are using hormonal contraception;
  6. Female subjects must not be breastfeeding or pregnant.

Exclusion criteria

Exclusion Criteria:

  1. Positive results at screening for , , or ;
  2. No use of tobacco products, as well as electronic cigarettes, within 14 days of Study Day 1 or unwilling to abstain during study participation;
  3. A medical history or clinical evidence of any clinical condition that may, in the opinion of the Investigator or Medical Monitor, impact on the subject's ability to participate in the study, or on the study results;
  4. Current or recent respiratory or other infection within 14 days of screening;
  5. Presence or history of significant allergy requiring treatment;
  6. abnormalities on ;
  7. Vital signs representing abnormal systolic blood pressure and/or abnormal diastolic blood pressure;
  8. Safety laboratory abnormalities at screening or Study Day 0 which are clinically significant;
  9. Subject has a history of drug abuse or alcohol abuse in the past 2 years or current evidence of such abuse or addiction;
  10. A positive urine drug screen test at screening or admission to the study facility;
  11. A positive breathalyzer for alcohol at screening or admission to the study facility;
  12. A positive pregnancy test at screening or admission to the study facility;
  13. Abstinence from alcohol must be employed from 72 hours before Study Day 1 and throughout the duration of study participation;
  14. Use of chronic prescription medications within 90 days, with the exception of hormonal (or contraceptive device containing hormonal contraceptive) being taken by female subjects within 14 days, or over-the-counter (OTC) medications, including vitamin, herbal, and mineral supplements, within the 7 days prior to Study Day 1 and throughout study participation;
  15. Received an drug or investigational vaccine within 30 days, or use of an investigational medical device within 30 days prior to Study Day 1;
  16. Any prior use of vapendavir or inclusion in a previous vapendavir investigational study or ongoing participation in a vapendavir investigational study;
  17. Donation or loss of whole blood within 60 days or plasma within 14 days of Study Day 1 or anytime from screening to 30 days after completion of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Vapendavir Capsule, 264 mg

    Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules

    Drug: vapendavir 132 mg capsule

  • Experimental
    Vapendavir Tablets, 264 mg

    Vapendavir free base tablets containing 264 mg of vapendavir

    Drug: vapendavir 264 mg tablet

  • Experimental
    Vapendavir Oral Suspension, 264 mg

    Vapendavir free base as a 24 mg/mL oral suspension

    Drug: vapendavir 24 mg/mL oral suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Relative oral bioavailability, as applicable

    Time frame: Study Day 0 - 17

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Study Day 0 - 17

  3. Time at which Cmac was observed (Tmax)

    Time frame: Study Day 0 - 17

  4. Area under the plasma concentration time curve from time ) to the last measureable plasma concentration (AUC 0-last)

    Time frame: Study Day 0 - 17

07

Study locations

1 site
  • Aviragen Investigational Site
    Saint Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016 and a primary completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2016
First posted
Aug 24, 2016
Start
Jun 2016
Primary completionActual
Aug 2016
Last update
Nov 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02877264
Responsible party
Sponsor
First posted
Aug 24, 2016
Start date
Jun 2016
Primary completion
Aug 2016
Last update
Nov 26, 2018

Study contacts

Anna Novotney-Barry
study director · Aviragen Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vapendavir

Start the discussion